Dow Today: Johnson & Johnson (JNJ) Lower

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

The Dow Jones Industrial Average ( ^DJI) is trading down 87.0 points (-0.5%) at 16,371 as of Tuesday, Jan 21, 2014, 12:35 p.m. ET. During this time, 237.8 million shares of the 30 Dow components have changed hands vs. an average daily trading volume of 360.6 million. The NYSE advances/declines ratio sits at 1,848 issues advancing vs. 1,149 declining with 162 unchanged.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Holding back the Dow today is Johnson & Johnson (NYSE: JNJ), which is lagging the broader Dow index with a $2.03 decline (-2.1%) bringing the stock to $93.03. This single loss is lowering the Dow Jones Industrial Average by 15.36 points or roughly accounting for 17.7% of the Dow's overall loss. Volume for Johnson & Johnson currently sits at 9.2 million shares traded vs. an average daily trading volume of 7.2 million shares.

Johnson & Johnson has a market cap of $268.21 billion and is part of the health care sector and drugs industry. Shares are up 3.8% year to date as of Friday's close. The stock's dividend yield sits at 2.8%.

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. The company has a P/E ratio of 21.2, above the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Johnson & Johnson as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, reasonable valuation levels and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
null

If you liked this article you might like

Crazy Weak U.S. Dollar Will Make These 10 Companies Huge Winners

Cramer: Goldman's Downgrade Of J&J Is 'Questionable'

Johnson & Johnson Stock Sinks, Goldman Downgrades to 'Sell'

The Best Companies for Women

Ridiculously Weak U.S. Dollar Will Make These 10 Companies Huge Winners